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PL-01 Anti-TB drug resistance surveillance in China
Y.L. Zhao*, G.L. Jiang, Y.H. Liu. National Tuberculosis
Reference Laboratory, CDC, China
Background: China is one of the heavy TB burden countries
with the number of TB cases ranked second in the
world. In the recent years, Although China has effectively
implemented DOTS strategy, Drug resistance-TB is one of
main constraint factors of TB control in China.
Objectives: To study the trends of drug resistant
tuberculosis prevalence in China.
Methods: The data from 1996 to 2006 in 13 provinces
(WHO/IUATLD drug resistance surveillance (DRS) project)
of which standardized method recommended by WHO in
sampling, cases intake, laboratory examination methods
were used to analyze the drug resistance prevalence
situation in survey regions. Results The data show that the
drug-resistant tuberculosis varied widely across different
provinces of China, initial drug resistance rate and
acquired drug resistance rate were 14.8 42.1% and 33.7 66%
respectively.
Conclusion: Drug resistant-TB prevalence is severe problem
in some regions of China. Effective measure should be
taken to contain the transmission of drug resistance strains
of tuberculosis, Nationwide anti-TB drug resistance survey
seems to be needed to investigate the situation of drug
resistance situation of whole country to provide scientiﬁc
basis on evaluation the implementation of the NTP.
PL-02 A novel technology for rapidly and sensitive assay
to detect changes in TCR Vb clonality following
antigen driven speciﬁc immune responses in
human and animal models
Z.C. Kou*. BioMed Immunotech, Inc., USA
Academic and clinical investigators have continuously
sought for prognostic or surrogate markers can monitor
T-cell immune responses following viral infections, tumors,
autoimmune disease, bone marrow transplantation, and
especially in monitoring efﬁcacy of vaccines and treatment
therapies. We have recently developed a novel T-cell
receptor (TCR) clonality/diversity assay in human and
animal models for this purpose. The method is specially
designed with one step multiple-PCR ampliﬁcations and a
simple agarose gel assay. The most important features of
the assay are that they require neither a DNA-sequencer nor
an initial cDNA synthesis step. The entire process requires
only a few hours, including PCR ampliﬁcation time, by
comparison, the DNA sequencer-based spectratyping assay
requires at least 2 or 3 days to complete, and costs are
much lower. As an investigative tool, the novel assay can be
used to study various diseases related to immune-mediated
disorders including viral infections, tumors, autoimmune
diseases, immune response following vaccination, and
response after bone marrow transplantation. As a diagnostic
tool, it can be used to monitor disease progression and track
curative effects of antiviral or anti-tumor treatments.
PL-03 Harnessing multidrug resistance gene expression
for effective antifungal strategies by a natural
product berberine
N. Sun1,2,6, F.H. Song1, G. Pei1,6, H.Q. Dai1, H. Gao1,
M. Liu1, C.Z. Fu1,6, C.S. Zheng1, J. Bian1,3,6, Y.J. Tong1,
J. Wang1,3,6, B. Ren1,6, H.L. Chen1, Y. Song1, X.L. Hu1,
Z.H. Liu1, X.P. Chen4, Y.Y. Jiang5, L.X. Zhang1,3,4,7 *.
1Institute of Microbiology, Chinese Academy of Sciences,
Beijing 100080, China, 2Institute of Oceanology, Chinese
Academy of Sciences, Qingdao 266071, China, 3South
China Sea Institute of Oceanology, CAS, Guangzhou,
China, 4Guangzhou Institute of Biomedicine and Health,
CAS, 510663, China, 5Department of Pharmacology,
Second Military Medical University, 200433, China,
6Graduate University, CAS, Beijing 100049, China, 7SynerZ
Pharmaceuticals Inc., Lexington, MA 02421, USA
Multidrug-resistance pumps (MDR) in microbes and cancer
cells are powerful defense mechanisms which confer
resistance to chemically unrelated drugs. A major challenge
in developing efﬁcacious antibiotics against drug-resistant
pathogens is to identify compounds that could sense, inhibit
and counteract MDR functions. In the human pathogen
Candida albicans, MDR1p plays a key role in clinical isolates
with azole-resistance. Here we report an unexpected
function of MDR1 in elevating the sensitivity of fungal
pathogen to berberine for enhanced therapeutic efﬁcacy.
Berberine, a widely used traditional Chinese medicine
identiﬁed as a potent fungicidal cofactor from our high
throughput synergy screening (PNAS 2007; 104: 4606),
is highly active against azole-resistant fungal pathogens.
It appears that the elevated expression of MDR1 in
resistant fungal strains confers sensitivity to berberine,
showing enhanced cell killing with much reduced amount
of berberine (Fig 1). This effect of MDR1 overexpression
is at least in part attributed to enhanced accumulation
of berberine. In support of this notion, a number of
berberine structural analogues exhibited a similar MDR1-
dependent antifungal activity (Fig 2). Berberine is indeed
highly efﬁcacious in inhibiting the growth of azole-resistant
clinical C. albicans isolates with upregulated MDR1 from
HIV infected patients. It seems that nature outsmarted
the defense mechanisms of fungal pathogen by using
MDR1-dependent cytotoxic agents like berberine and its
analogues. Our study reveals a novel function of MDR1
in raising sensitivity of drug-resistant fungal pathogens to
selected natural products and thus shed lights on novel
antifungal therapy.
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PL-04 Communicable diseases surveillance lessons
learned from developed and developing
countries: literature review
N. Sahal1 *, R. Reintjes2, A.R. Aro1. 1Unit for Health
Promotion Research, Institute of Public Health,
University of Southern Denmark (SDU), Esbjerg, Denmark,
2Department of Public Health, Faculty of Life Sciences,
Hamburg University of Applied Sciences, Hamburg,
Germany
Background: Surveillance of infectious diseases is
recognized as the cornerstone of public health decision-
making and practice. The aim of the evaluation of
communicable diseases surveillance systems (CDSS) is
ensuring that communicable diseases are monitored
efﬁciently and effectively. The aim of this paper is to
reﬂect on the experiences of both developed and developing
countries in the evaluation of CDSS in order to learn lessons
from these experiences to improve systems everywhere.
Methods: A literature review of studies published in English
in PubMed and data bases of the World Health Organization
(WHO), and Center of Diseases Control (CDC) from 1981
to 2007 was undertaken assessing CDSS. The studies
were divided into those from developed and developing
countries.
Results: A total of 32 studies were included, 20
from developed and 12 from developing countries. Both
developed and developing countries faced difﬁculties in
CDSS. Studies from the developed countries have been
analyzed based on the quality of the system alone. In
developing countries, most of the studies have been on
the integrated diseases surveillance (IDSR) and have been
performed shortly after the adoption of the IDSR. Thus it
might be too early to make a fair evaluation. Some of the
systems over-centralized, while some lacked private health
sector involvement in the system. Further, some of the
systems were affected by conﬂicts and civil wars which are
common problems in developing countries.
Conclusion: None of the countries had ideal CDSS. The
strategy of integrated diseases surveillance seems to be
functioning well especially in Africa.
PL-05 MIDAS Public Disease Model
P. Cooley*, J. Cajka, B. Chasteen, L. Ganapathi,
W. Wheaton, D. Wagener. RTI International, Box 12194,
RTP, N.C., 27709, USA
The MIDAS∗ Public Disease Model is an agent based model
(ABM) that uses synthetic data to simulate and describe
inﬂuenza transmission within speciﬁc U.S. geographic areas.
Each person in the region of interest is an agent and each
agent is described by a number of demographic traits that
deﬁne the social network interactions that the agents are
part of. The agent traits that compromise the synthetic
data were developed from US census, National Education
Association and a provider of business information, InfoUSA,
data sources. They represent the U.S. population at the
time of the 2000 Census. The data include:
• A household in every Census tract that corresponds to a
household in the 2000 Census.
• Persons who live in those households within the tracts
such that their important Census tract level demographic
characteristics match those of the 2000 Census.
• Locations of all public and private schools as well as
pre-school and daycare facilities in the US that match a
variety of publicly available sources. Location, enrollment
and grade-level information are also deﬁned.
• An age-speciﬁc school assignment plan that deﬁnes the
schools attended by each school eligible person in the
population.
